Fig. 2: Changes in primary outcomes from baseline to 4 weeks, 8 weeks, 3 months and 6 months in the matched population. | Schizophrenia

Fig. 2: Changes in primary outcomes from baseline to 4 weeks, 8 weeks, 3 months and 6 months in the matched population.

From: Associations between second-generation antipsychotics and metabolic outcomes in patients with schizophrenia and metabolic abnormalities

Fig. 2: Changes in primary outcomes from baseline to 4 weeks, 8 weeks, 3 months and 6 months in the matched population.The alternative text for this image may have been generated using AI.

A Within-group changes in the proportion of patients with metabolic syndromes in the group of low-risk SGAs. B Within-group changes in the proportion of patients with metabolic syndromes in the group of high/intermediate-risk SGAs. C Between-group changes in the proportion of patients with metabolic syndromes. Changes are estimated as risk differences with 95% confidence intervals by chi square tests. D Within-group changes in the number of metabolic abnormalities in the group of low-risk SGAs. E Within-group changes of the number of metabolic abnormalities in the group of high/intermediate-risk SGAs. F Between-group changes of the number of metabolic abnormalities. Changes are estimated as mean differences with 95% confidence intervals by paired t-tests. SGA second-generation antipsychotics, RD risk difference, MD mean difference.

Back to article page